Biohaven shares are trading lower after the FDA refused to review the company's troriluzole marketing application as primary endpoint was not met.
Portfolio Pulse from Benzinga Newsdesk
Biohaven's shares are trading lower after the FDA declined to review the company's troriluzole marketing application because the primary endpoint was not met.
July 27, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biohaven's stock price is expected to decrease in the short term due to the FDA's refusal to review the company's troriluzole marketing application.
The FDA's refusal to review Biohaven's troriluzole marketing application is a significant setback for the company. This news is likely to negatively impact investor sentiment, leading to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100